Clinical Trials Logo

Metabolic Complication clinical trials

View clinical trials related to Metabolic Complication.

Filter by:

NCT ID: NCT06360666 Enrolling by invitation - Mortality Clinical Trials

Clinical Outcomes in Adult Patients Undergoing Laparoscopic Surgery Under Neuraxial Anesthesia

NEURAX
Start date: October 1, 2022
Phase:
Study type: Observational

The goal of this observational study is to learn about postoperative mortality and postoperative length of stay outcomes after abdominal laparoscopic major surgery. The main question it aims to answer is: Does general anesthesia lower complications compared to loco-regional anesthesia (keeping the patient spontaneously breathing and sedated) in laparoscopic abdominal major surgery? Participants are followed for neurological sequelae for 90 days following surgery

NCT ID: NCT05488223 Completed - Insulin Resistance Clinical Trials

Supplementation With PUFA´s in Obese Children

PUFA
Start date: February 17, 2014
Phase: N/A
Study type: Interventional

Introduction. Insulin resistance (IR) accompanies practically half of children with obesity. This alteration is the border between what can be reversible or permanent. Among the comorbidities associated with IR are T2D and cardio and cerebrovascular diseases, which are the leading causes of death in Mexico. It has been said that the prevention of obesity rather than its treatment is the way to contain this problem. It has been proposed to supplement obese children with IR with ω-3 polyunsaturated fatty acids (PUFA) or ω-9 monounsaturated fatty acids (MUFA) to determine their ability to reverse these alterations. Objetive. To evaluate the effect of supplementing PUFA ω-3, PUFA ω-9 or both, on the change in anthropometric and metabolic parameters in obese children with IR. Methods. Clinical trial, randomized triple-blind, in which obese children with IR participated. Intervention. Three groups were integrated that received one of the following treatments for three months: Group 1: PUFA ω-3 1.8 g/day; Group 2: PUFA ω-3 0.9 g/day + PUFA ω-9 0.9 g/day (avocado oil). Group 3: MUFA ω-9 1.8 g/day. Tracing. For 2 more months he continued his clinical surveillance. Anthropometric and metabolic profile measurements were made at baseline, 3 and 5 months. Throughout the study, all three child groups received nutritional counseling, but no calorie-restricted diets or exercise programs were used.

NCT ID: NCT05451992 Completed - Clinical trials for Overweight and Obesity

Microbiome-Tailored Food Products Based On Typical Mediterranean Diet Components

SUPERFOOD 19-2
Start date: February 15, 2021
Phase: N/A
Study type: Interventional

The composition and functions of the microbiome impact human metabolism and health status. Diet plays a fundamental role in shaping the structure of the gut microbiome, modulating the interaction between the gut microbiome and the human host. Western dietary patterns including a high consumption of red and processed meat, refined grains and sugars, and dairy products have been associated with a high incidence of chronic diseases. It is widely recognised that there is a higher consumption of plant-based foods in Mediterranean countries than in other Western countries. The Mediterranean diet involves a high intake of fruits, vegetables, legumes, nuts, minimally processed cereals, moderate consumption of fish and a low consumption of saturated fats, meat and dairy products with regular intake of extra virgin olive oil. The Mediterranean diet reduces the incidence of cardiovascular, metabolic and neurodegenerative diseases. Interesting results emerged from the evaluation of the microbiome-metabolome interaction, which shows that individuals with the highest adherence to the Mediterranean diet had much higher levels of short-chain fatty acids (SCFAs) and increased levels of the beneficial fiber-degrading bacteria compared to subjects with low adherence to the Mediterranean diet. The study of the effect on the microbiota of specific foods with anti-inflammatory/antioxidant properties is interesting and of potential clinical impact.

NCT ID: NCT04966754 Not yet recruiting - Obesity Clinical Trials

Data Driven Behavior Intervention and Medical Outcome Evaluation of Patients' Comprehensive Monitoring

Start date: August 1, 2021
Phase:
Study type: Observational

During the study, the resuscitation room, general wards and ICU were installed fixed or mobile acquisition devices in the resuscitation room, the emergency department of Peking Union Medical College Hospital, and the collection platform was set up. Patients with acute diseases (infection, diabetes complications, etc.) caused by metabolic syndrome (obesity, diabetes, etc.) were selected after informed consent. All medical intervention behaviors, relevant medical records and medical outcome records within the collection scope of the device platform were collected prospectively . And regular follow-up, guidance of patients with metabolic syndrome control, while collecting all the lifestyle characteristics of patients, some patients with metabolic cabin research, and observe the relevant medical outcomes. After that, all the collected data were coded, and the influence of all lifestyle and medical behavior interventions on patients' medical outcomes was studied by artificial intelligence method.

NCT ID: NCT04865965 Recruiting - Obesity Clinical Trials

Effects of a Single Bout of Exercise on Transcriptomics and Metabolomics in Adipose Tissue

Start date: May 27, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effects of a single bout of exercise on changes in the genes and small molecules in blood and fat tissue, before and after a bout of exercise. This research may contribute to a better understanding of the beneficial effects of exercise on the body.

NCT ID: NCT04787952 Completed - Healthy Clinical Trials

Insight Into New Brown Adipose Tissue Activators.

Start date: October 1, 2016
Phase:
Study type: Observational

The general purpose of the study was to provide new information about the role of macronutrients intake, metabolomics, proteomics and microRNA on BAT activation. The invesigator evaluated BAT activity and whole body energy consumption under cold stimulation in two gruops of healthy males aged 21-43 years old with normal BMI ( 19-25kg/m2) and in overweight/obese subjects.

NCT ID: NCT04642066 Suspended - Clinical trials for Cardiovascular Risk Factor

Cold Water Immersion and Atherosclerosis, Inflammation, Fat Accumulation and Lipid Profile Parameters

Start date: October 25, 2018
Phase: N/A
Study type: Interventional

The impact of the environment on human health is considerable. An important factor is the effect of temperature on the human body, where either the effects of short-term exposure to extreme temperatures (cryotherapy, sauna, etc.) or the long-term environmental impact are monitored. The study was focused on research of the long-term effect of repeated CWI on atherogenesis, lipid parameters and fat distribution.

NCT ID: NCT03864744 Enrolling by invitation - Diabetes Mellitus Clinical Trials

Hepatic Histology and Metabolism Following Total Pancreatectomy and Pancreaticoduodenectomy

Start date: January 30, 2019
Phase:
Study type: Observational

The objective of the study is to investigate the development of NAFLD following total pancreatectomy and pancreaticoduodenectomy and to explore the histological and metabolic changes following the procedures.

NCT ID: NCT03864068 Recruiting - Insulin Resistance Clinical Trials

Inositol Supplementation to Treat PCOS (INSUPP-PCOS)

INSUPP-PCOS
Start date: January 24, 2020
Phase: Phase 2
Study type: Interventional

To determine if Inositol, a dietary supplement, will improve ovarian and adrenal androgen excess in women with Polycystic Ovarian Syndrome(PCOS).

NCT ID: NCT03544541 Completed - Clinical trials for Type1 Diabetes Mellitus

Cardiometabolic Risk in Children With Type 1 Diabetes.

Start date: January 5, 2018
Phase:
Study type: Observational [Patient Registry]

To access the relationship between metabolic control of children and adolescents with type 1 diabetes and cardiometabolic risk through noninvasive imaging modalities to assess the early vasculature changes.